- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
March 1, 2021Amy Churan Named an Insurance Trailblazer by National Law Journal
-
March 1, 2021Firm, Partner Recognized by Managing IP
-
3/1/2021Robins Kaplan Recognized in 2021 World Trademark Review 1000
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
March 1, 2021Financial Daily Dose 3.1.2021 | Top Story: Walmart Poaches Goldman Bankers in Bid to Bolster Fintech Venture
-
February 26, 2021Financial Daily Dose 2.26.2021 | Top Story: Rising Long-Term Bond Yields Blamed for Jumpy Markets
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Robins Kaplan Named “Recommended Firm” for Hatch-Waxman Litigation; Four Partners “life Sciences Stars”
October 12, 2020
Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm nationwide for generic pharmaceutical companies. In addition, Jake Holdreith, Jeffrey Hovden, Oren Langer, and Ronald Schutz have been named “Life Science Stars.”
- Jake Holdreith is a member of the firm’s Executive Board. He has tried jury cases to multi-million dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Holdreith is known for work in in the pharmaceutical, chemical, and electronics industries and has handled cases in the United States, Europe, and Asia.
- Jeff Hovden practices in the area of patent litigation, with a focus on generic pharmaceutical patent cases under the Hatch-Waxman Act and within the biotechnology industry. He routinely advises clients on their intellectual property portfolios and has extensive experience with the Food, Drug, and Cosmetic Act's drug-approval provisions and their attendant regulations.
- Oren Langer’s intellectual property litigation experience spans various industries including pharmaceuticals (under the Hatch-Waxman regulatory framework), chemicals, telecommunications, video gaming, retail services, and representing clients in Rate Court proceedings. Prior to his legal career, Mr. Langer earned a Bachelor's degree in chemistry and interned and worked at Bristol-Myers Squibb and Pharmacopeia as an organic chemist.
- Ronald Schutz is chair of the firm’s Executive Board. He is a fellow of the American College of Trial Lawyers and has been recognized by many legal organizations and publications as one of the top lawyers in the country, including The National Law Journal, which named him one of the “Top 10 Winning Litigators in the United States.” He has won a nine-figure and multiple eight-figure jury verdicts, and has secured victories against behemoths such as Apple, Clear Channel, Sony, and Canon.
Related Professionals
Related Publications
Fourth Quarter
ANDA Approvals
GENERICally Speaking Winter 2021
Fourth Quarter
ANDA Litigation Settlements
GENERICally Speaking Winter 2021
Fourth Quarter
Generic Launches
GENERICally Speaking Winter 2021
Fourth Quarter
New ANDA Cases
GENERICally Speaking Winter 2021
December 21, 2020
Eli Lilly & Co. v. Apotex, Inc.
GENERICally Speaking Winter 2021
Related News
September 27, 2018
August 2, 2018
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.